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The cJun NH2-terminal kinase (JNK) stress signaling
pathway is implicated in the metabolic response to
the consumption of a high-fat diet, including the
development of obesity and insulin resistance. These
metabolic adaptations involve altered liver function.
Here, we demonstrate that hepatic JNK potently re-
presses the nuclear hormone receptor peroxisome
proliferator-activated receptor a (PPARa). Therefore,
JNK causes decreased expression of PPARa target
genes that increase fatty acid oxidation and keto-
genesis and promote the development of insulin
resistance. We show that the PPARa target gene
fibroblast growth factor 21 (Fgf21) plays a key role
in this response because disruption of the hepatic
PPARa-FGF21 hormone axis suppresses the meta-
bolic effects of JNK deficiency. This analysis iden-
tifies the hepatokine FGF21 as a critical mediator of
JNK signaling in the liver.
INTRODUCTION
The cJun NH2-terminal kinase (JNK) signaling pathway plays
an important role in the development of obesity and insulin resis-
tance (Sabio and Davis, 2010). Indeed, JNK1 deficiency in mice
prevents the obesity and insulin resistance caused by hyperpha-
gia or the consumption of a high-fat diet (HFD) (Hirosumi et al.,
2002). Studies of tissue-specific JNK-deficient mice demon-
strate that these obesity and insulin resistance phenotypes can
be separated. Thus, JNK regulation of the hypothalamic-pituitary
hormone axis that regulates energy expenditure is critically
required for the development of diet-induced obesity (Belgardt512 Cell Metabolism 20, 512–525, September 2, 2014 ª2014 Elsevieet al., 2010; Sabio et al., 2010a; Vernia et al., 2013). In contrast,
JNK function in peripheral tissues, including fat, muscle, and in-
flammatory cells, contributes to diet-induced insulin resistance
(Sabio et al., 2008, 2010b; Han et al., 2013).
Consuming a HFD increases the blood concentration of free
fatty acids (Kahn et al., 2006) and causes JNK activation medi-
ated by the mixed-lineage protein kinase pathway (Jaeschke
and Davis, 2007; Kant et al., 2013). Activated JNK contributes
to obesity development by increasing activating protein 1
(AP1)-dependent Dio2 gene expression in the anterior pituitary
gland (Vernia et al., 2013). In contrast, targets of JNK signaling
that cause insulin resistance are unclear. Early studies sug-
gested that phosphorylation of the insulin receptor adaptor pro-
tein IRS1 by JNK causes insulin resistance (Aguirre et al., 2000),
but subsequent studies have not confirmed this conclusion
(Copps et al., 2010). More recently, JNK-mediated regulation
of adipokines (Sabio et al., 2008) and inflammatory cytokines
(Han et al., 2013) has been implicated in the development of
insulin resistance. For example, the promotion of hepatic insulin
sensitivity caused by JNK deficiency in adipocytes and myeloid
cells is associated with defects in adipokine and cytokine
expression (Sabio et al., 2008; Han et al., 2013). These data
indicate that JNK-mediated hepatic insulin resistance may be
caused by JNK function in nonhepatic cells (Sabio et al., 2008;
Han et al., 2013). This conclusion is consistent with the finding
that whole-body JNK1 deficiency (Hirosumi et al., 2002), but
not hepatic JNK1 deficiency (Sabio et al., 2009), protects against
HFD-induced insulin resistance. Therefore, the function of he-
patic JNK is unclear.
The purpose of this studywas to re-evaluate the role of hepatic
JNK in the metabolic stress response caused by the consump-
tion of a HFD. It is established that JNK is encoded by the
Jnk1 and Jnk2 genes in liver (Davis, 2000). We show that mice
with compound hepatic ablation of both genes (Jnk1 and Jnk2)
exhibit systemic protection against HFD-induced insulin resis-
tance. Moreover, we demonstrate that the peroxisomer Inc.
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tor 21 (FGF21) hormone axis contributes to metabolic regulation
by hepatic JNK.
RESULTS
Establishment of Mice with JNK Deficiency in the Liver
To test the role of hepatic JNK, we compared control mice (LWT)
and mice with hepatocyte-specific deficiency of JNK1 (LD1),
JNK2 (LD2), or JNK1 plus JNK2 (LD1,2) (Figures 1A and 1B).
HFD-induced JNK activation in the liver of LWT mice was partially
suppressed in LD1 and LD2 mice (Figure 1C). In contrast, hepatic
JNK activity was not detected in LD1,2 mice (Figure 1C). These
data indicate that JNK1 and JNK2 may serve partially redundant
functions in the liver and confirm the absence of hepatic JNK
activity in LD1,2 mice. We employed these mouse strains in order
to examine the metabolic consequences of hepatic JNK
deficiency.
Hepatic JNK Deficiency Reduces Diet-Induced Obesity
We found that hepatic JNK deficiency caused no change in body
mass when mice were fed a chow diet (Figure 1D; Figures S1A
and S1B available online). Similarly, HFD-fed LWT mice and LD1
mice developed equal obesity (Figures 1D, S1A, and S1B). In
contrast, HFD-fed LD2 mice and LD1,2 mice gained less fat
mass than HFD-fed LWT mice (Figures 1D, S1A, and S1B). These
data indicate that JNK2 deficiency, rather than JNK1 deficiency,
most closely mimics the phenotype of compound deficiency of
JNK1 plus JNK2.
The reduced obesity of LD1,2 mice in comparison to LWT mice
was associated with reduced adipose tissue mass (Figure S1B),
reduced VLDL triglyceride in serum (Figures S1D and S1E),
reduced total serum triglyceride (31.7 ± 0.03 mg/dl in compar-
ison to 64.8 ± 0.09 mg/dl; mean ± SEM; n = 8; p < 0.03),
reduced hepatic expression of lipogenic genes, including
Srebf1 and Fasn (Figures S1F and S1G), and reduced de
novo hepatic lipogenesis (Figure S1H). Altogether, these data
demonstrate that hepatic JNK deficiency causes dysregulated
lipid metabolism.
Hepatic JNK Deficiency Increases Insulin Sensitivity
The HFD-fed LD1,2 mice showed improved tolerance to glucose,
insulin, and pyruvate (Figures 1E–1G). Hyperinsulinemic-eugly-
cemic clamp studies demonstrated reduced hepatic glucose
production, increased hepatic insulin action, improved whole-
body insulin sensitivity (detected by increased glucose infusion
rates during the clamps), and increased whole-body glycogen
plus lipid synthesis (Figures 1H–1K). These data demonstrate
that hepatic JNK deficiency causes protection of mice against
HFD-induced insulin resistance.
We performed biochemical studies of insulin signaling bymea-
surement of AKT activation in LWT and LD1,2 mice. This analysis
demonstrated that LD1,2 mice were partially protected against
the HFD-induced suppression of insulin-stimulated AKT activa-
tion in liver, adipose tissue, and skeletal muscle that was de-
tected in LWT mice (Figures 1L–1N). These data confirm the
conclusion that HFD-fed LD1,2 mice exhibit a systemic increase
in insulin sensitivity in comparison to LWT mice. The increased
insulin sensitivity of LD1,2 mice correlates with reduced HFD-Cell Meinduced islet hypertrophy, hyperinsulinemia, and suppression
of glucose-stimulated insulin secretion (Figures 2A–2D). More-
over, HFD-induced hyperglycemia was significantly suppressed
in LD1,2 mice compared with LWT mice (Figures 2E–2F).
The improved insulin sensitivity of HFD-fed LD1,2 mice con-
trasts with our previous analysis of LD1 mice with liver-specific
JNK1 deficiency that exhibit increased insulin resistance
compared with LWT mice (Sabio et al., 2009). This analysis sug-
gests that hepatic JNK2 may play a critical role in glycemic
regulation. Indeed, HFD-fed LD2 mice exhibited increased
glucose tolerance, reduced islet hypertrophy, and reduced
hyperinsulinemia in comparison to HFD-fed LWT mice (Figures
S2A–S2F). The HFD-fed LD2 mice also exhibited increased insu-
lin sensitivity in hyperinsulinemic-euglycemic clamp studies (Fig-
ures S2GS2M). Nevertheless, these glycemic phenotypes of
LD2mice (Figure S2) aremodest in comparison to LD1,2 mice (Fig-
ures 1 and 2). Altogether, these data indicate that LD1 mice and
LD2 mice exhibit different glycemic phenotypes and that LD2
mice, and especially LD1,2 mice, show improved control of blood
glucose concentration compared with LWT mice.
The mechanism that accounts for the differential effects of he-
patic JNK1andJNK2deficiency is unclear. Previous studies have
established that isoforms of JNK with different protein kinase
activities are derived by alternative splicing of primary transcripts
of the Jnk1 and Jnk2 genes (Davis, 2000). Indeed, JNK substrate
specificity is determined by the mutually exclusive inclusion of
exons 7aor 7b in Jnk1 and Jnk2mRNA that encode JNK isoforms
a and b (Gupta et al., 1996). Analysis of hepatic Jnk mRNA
demonstrated that the major JNK isoforms in liver correspond
to JNK1b and JNK2a (Figure S1C). This pattern of alternative
splicing of Jnk mRNA may contribute to the differential pheno-
types caused by ablation of the hepatic Jnk1 or Jnk2 genes.
Hepatic JNK Deficiency Increases Fatty Acid Oxidation
Hepatic gene expression in chow- and HFD-fedmice was exam-
ined with RNA sequencing (RNA-seq) analysis (Figures S3A and
S3B). JNK deficiency caused increased gene expression in HFD-
fed mice (Figures S3C–S3E). Gene Ontology analysis demon-
strated that LD1 mice and LD2 mice were markedly different
and that LD2 mice resembled LD1,2 mice (Figures S3F–S3H).
Therefore, differentially regulated genes that contribute to the
hepatic phenotype of the JNK-deficient mice were identified by
comparing gene expression patterns with the glycemic pheno-
type of the mice (LD1 < LWT < LD2 < LD1,2). Genes downregulated
in LD1 mice and upregulated in LD1,2 mice to a greater extent than
LD2 mice in comparison to LWT mice were identified, including
Fgf21 (Figures 3A and 3B). GeneOntology analysis identified sig-
nificant (padj < 0.001) association of hepatic JNK1 plus JNK2
deficiency with the PPAR pathway and oxidative metabolism
(Figure 3C).
To test whether JNK deficiency increases oxidative meta-
bolism, we investigated mitochondrial oxygen consumption by
LD1,2 and LWT hepatocytes incubated with different substrates.
We found that JNK deficiency caused increased mitochondrial
oxygen consumption in the presence of palmitate (Figure 3D). In
contrast, mitochondrial oxygen consumption by LD1,2 hepato-
cytes metabolizing glucose or pyruvate/lactate was decreased
(Figure 3D). Moreover, glucose production by LD1,2 hepatocytes
metabolizing lactate and pyruvate was increased in comparisontabolism 20, 512–525, September 2, 2014 ª2014 Elsevier Inc. 513
(legend on next page)
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tion in vitro was associated with increased expression of the
gluconeogenic genes G6pc and Pck1 by LD1,2 hepatocytes
compared with LWT hepatocytes (Figure S1I). We also found that
lactate production by LD1,2 hepatocytes metabolizing glucose
was increased comparedwith LWT hepatocytes (Figure 3F). These
effects of JNK deficiency were associatedwith increased expres-
sion of citric acid cycle and respiratory chain genes along with
increased expression of Pdk4, an inhibitor of the oxidative meta-
bolism of pyruvate (Figure 3G). These data demonstrate that
JNK deficiency increases the glycolytic conversion of glucose to
lactate and selectively promotes the oxidation of fatty acids.
Hepatic JNK Deficiency Activates the PPARa Pathway
The hepatic PPARa pathway (and PPARb/PPARd in fat andmus-
cle) increases fatty acid oxidation by peroxisomes, mitochon-
dria, and the endoplasmic reticulum (Evans et al., 2004; Pyper
et al., 2010). PPARa pathway activation and increased fatty
acid oxidation in the liver of LD1,2 mice are reflected by increased
PPARa target gene expression (Figure S3B), including genes
required for b oxidation in peroxisomes (Figure 3I) andmitochon-
dria (Figure 3J) along with u oxidation in the endoplasmic retic-
ulum (Figure 3K) in comparison to LWT mice. The LD1,2 mice also
exhibited increased numbers of hepatic peroxisomes (Figures
4A and 4C), increased mitochondrial size (Figures 4B, 4D,
and 4E; consistent with reduced JNK-promoted mitochondrial
fission) (Leboucher et al., 2012), and reduced respiratory ex-
change ratio (Figure S4) in comparison to LWT mice. These
data are consistent with the presence of increased PPARa-path-
way-stimulated fatty acid oxidation in the liver of LD1,2 mice. The
increased fatty acid oxidation (Figure 3D), along with reduced
lipogenesis (Figures S1F–S1H), contributes to the reduced
hepatic steatosis detected in LD1,2 mice in comparison to LWT
mice (Figure 3H). Because treatment with PPARa agonists can
improve glycemia by increasing fatty acid oxidation (Evans
et al., 2004; Pyper et al., 2010), PPARa pathway activation may
contribute to the phenotype of LD1,2 mice (Figures 1 and 2).
The mechanism that mediates PPARa pathway activation in
JNK-deficient liver is unclear. Therefore, we examined PPARa-
dependent gene expression in primary hepatocytes. Studies ofFigure 1. Hepatic JNK Contributes to Diet-Induced Obesity and Insulin
(A) The liver, adipose tissue (epididymal), and skeletal muscle (gastrocnemius) of L
with antibodies to JNK and GAPDH.
(B) Genomic DNA isolated from the liver of LWT, LD1, LD2, and LD1,2 mice was exa
(C) Liver extracts prepared from mice fed a chow diet or a HFD (16 weeks) and
antibodies to a-tubulin and JNK. In vitro protein kinase assays (KA) with the su
activity. The amount of cJun and phosphorylated cJun (p-cJun) were detected
analysis, respectively.
(D) The fat and lean mass of chow- and HFD-fed (16 weeks) mice were measured
LWT and LD1,2 mice were detected (**p < 0.01, ***p < 0.001).
(E and F) Glucose (GTT) and insulin (ITT) tolerance tests were performed on mice
(G) Pyruvate (PTT) tolerance tests were performed on mice fed HFD (16 weeks;
(H–K) Insulin sensitivity wasmeasured with hyperinsulinemic-euglycemic clamps
production (HGP) during the clamp, hepatic insulin action (expressed as insulin-me
plus lipid synthesis (mean ± SEM for 6–8 experiments) are presented. Statistica
(L–N) Chow- or HFD-fed LWT and LD1,2 mice were starved overnight and then
epididymal adipose tissue, and gastrocnemius muscle extracts (prepared 15 min
AKT (mean ± SEM; n =5–6; *p < 0.05). Representative extracts were also examin
pThr308), and GAPDH (bottom).
See also Figures S1 and S2.
Cell Methree PPARa target genes (Acox1, Ehhadh, and Pdk4) demon-
strated no major differences in the amount of basal expression
between LD1,2 and LWT hepatocytes. Gene expression was
suppressed by treatment with the PPARa antagonists GW6471
or MK886 (Figure 5A). Treatment with the PPARa agonists
WY14043 or Fenofibrate caused increased gene expression by
LWT hepatocytes that was greatly potentiated in LD1,2 hepato-
cytes (Figure 5A). This increase in PPARa-dependent gene
expression was not caused by changes in the expression of
PPARa or its heterodimeric partner RXRa (Figure 5B). Reduced
expression of corepressors could contribute to increased
PPARa function (Perissi et al., 2010; Mottis et al., 2013), and pre-
vious studies have established that decreased NCoR1 expres-
sion can cause increased nuclear hormone receptor activity (Li
et al., 2011; Yamamoto et al., 2011). We found that hepatic
JNK deficiency decreased the expression of the PPARa core-
pressors NCoR1 and NRIP1 (Figures 5B and 5C). The reduced
expression of these corepressors may contribute to the meta-
bolic phenotype of LD1,2 mice because it is established that
reduced expression of NCoR1 (Mottis et al., 2013) or NRIP1
(Nautiyal et al., 2013) is sufficient to promote insulin sensitivity.
To confirm the conclusion that loss of JNKprotein kinase activ-
ity causes increased PPARa pathway activity, we examined the
effect of the selective inhibitor JNK-in-8 (Zhang et al., 2012).
This analysis demonstrated that inhibition of JNK protein kinase
activity caused increased PPARa target gene expression
(Ehhadh, Fgf21, and Pdk4) by primary hepatocytes treated with
the PPARa agonist Fenofibrate (Figure 5D). The JNK inhibitor
also caused decreased expression of Ncor1 mRNA (Figure 5D).
This observation indicates that the JNK inhibitor and Jnk gene
ablation cause a similar decrease in Ncor1 expression and in-
crease in PPARa pathway activity. However, the decrease in
Nrip1 expression detected in LD1,2 hepatocytes (Figures 5B and
5C) was not detected when wild-type hepatocytes were treated
with the JNK inhibitor (Figure 5D). The mechanism that accounts
for this differential regulation ofNrip1 expression is unclear, but it
is possible that short-term pharmacological JNK inhibition may
be insufficient to phenocopy the effects of chronic JNK loss-of-
function in LD1,2 hepatocytes. These data suggest that Ncor1,
rather than Nrip1, represents a key target of hepatic JNK.Resistance
WT, LD1, LD2, and LD1,2 mice were examined by immunoblot analysis by probing
mined by PCR analysis in order to detect Jnk and DJnk alleles.
starved overnight were examined by immunoblot (IB) analysis by probing with
bstrates GST-cJun and [g-32P]ATP were performed in order to measure JNK
by staining with Coomassie blue and Phosphorimager (Applied Biosystems)
by 1H-MRS analysis (mean ± SEM; n =8–10). Significant differences between
fed HFD (16 weeks; mean ± SEM; n = 35–50; **p < 0.01; ***p < 0.001).
mean ± SEM; n = 20–30; ***p < 0.001).
with conscious LWT and LD1,2 mice fed a chow diet or HFD. The hepatic glucose
diated percent suppression of basal HGP), glucose infusion rate, and glycogen
lly significant differences between LWT and LD1,2 mice are indicated (*p < 0.05).
administered insulin (1.5 U/kg body mass) by intraperitoneal injection. Liver,
postinjection) were examined (top) by multiplexed ELISA for pSer473-AKT and
ed by immunoblot analysis with antibodies to AKT, phospho-AKT (pSer473 and
tabolism 20, 512–525, September 2, 2014 ª2014 Elsevier Inc. 515
Figure 2. Effect of Liver-Specific JNK
Deficiency on Hyperinsulinemia
(A) Mice were fed a chow diet or HFD (16 weeks).
Sections of the pancreas were stained with an
antibody to insulin. The scale bar represents
100 mm.
(B) Relative islet size was measured with ImageJ
(mean ± SEM; n = 30; *p < 0.05).
(C) The mice were fasted overnight, and the
blood concentration of insulin was measured
(mean ± SEM; n = 16; *p < 0.05).
(D) Glucose-induced insulin secretion was exam-
ined using overnight fasted mice by intraperitoneal
injection of glucose and measurement of blood
insulin concentration (mean ± SEM; n = 8–10;
**p < 0.01).
(E and F) Mice were fed a chow diet or a HFD
(16 weeks). Blood glucose concentration in mice
fasted overnight or fed ad libitum was measured
(mean ± SEM; n = 35–50; *p < 0.05, **p < 0.01,
***p < 0.001).
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account for PPARa pathway activation, we used small hairpin
RNA (shRNA) to knock down hepatic Ncor1 expression with an
adenovirus-associated virus serotype 8 (AAV8) vector. Control
studies demonstrated that the AAV8-shNcor1 vector reduced
the expression of hepatic Ncor1 mRNA (Figure 5E). Expression
of PPARa target genes (Fgf21 and Pdk4) was increased in the
mice treated with the AAV8-shNcor1 vector in comparison to
mice treated with the control AAV8-shLuc vector (Figure 5E).
These data confirm that reduced NCoR1 expression is sufficient
to increase hepatic PPARa pathway activity.
Weperformedcomplementationassays to testwhether restora-
tion of NCoR1 expression suppressed the effect of hepatic JNK
deficiency to increase PPARa target gene expression. Indeed,
ectopic NCoR1 expression in the liver of LD1,2 mice reduced
expression of the PPARa target genes Acox1, Ehhadh, and Pdk4
(Figure 5F). Moreover, restoring NCoR1 prevented the effect of
JNK deficiency to cause improved glucose tolerance in HFD-fed
mice (Figure 5G). Altogether, these data confirm the conclusion516 Cell Metabolism 20, 512–525, September 2, 2014 ª2014 Elsevier Inc.that reduced NCoR1 expression contrib-
utes to the effects of JNK deficiency on
the hepatic PPARa signaling pathway.
A reduction in corepressor expression
in JNK-deficient hepatocytes (Figures 5B
and 5C) may cause not only increased
PPARa activity but also increased activity
of other nuclear hormone receptors,
including the thyroid hormone receptor
that binds NCoR1 (Ho¨rlein et al., 1995).
Indeed, reduced NCoR1 expression in
the liver caused increased expression
of the thyroid hormone receptor target
gene Dio1 (Figure 5E). To test this predic-
tion, we examined triiodothyronine (T3)-
stimulated gene expression in primary
hepatocytes isolated from LWT and LD1,2
mice. We found that JNK deficiencycaused significantly increased T3-stimulated expression of thy-
roid hormone receptor target genes (Figure S5A). Increased
expression of these genes in the liver of LD1,2 mice in comparison
to LWT mice in vivo was detected in the absence of significant
changes in the amount of blood thyroid hormone (Figures S5B
and S5C). These data support the conclusion that hepatic JNK
deficiency may increase the activity of multiple nuclear hormone
receptors by decreasing corepressor activity.
Hepatic JNK Deficiency and the PPARg Pathway
The PPARg pathway plays an important role in AP1-dependent
regulation of hepatic lipid metabolism (Hasenfuss et al., 2014).
The mechanism is mediated by increased expression of
PPARg2 that is promoted by cFos heterodimers with cJun/
JunB/JunD and is antagonized by Fra1/Fra2 heterodimers
with cJun (Hasenfuss et al., 2014). Because AP1 proteins are
key targets of the JNK signaling pathway (Davis, 2000), we
anticipated that hepatic JNK deficiency may regulate the
expression of both AP1 proteins and PPARg2. Indeed, hepatic
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Fra2, cFos, and FosB in HFD-fed mice (Figure S6A), but hepatic
JNK deficiency caused no significant change in the HFD-
induced expression of PPARg2 (Figure S6B). The absence of
a PPARg2 expression phenotype caused by hepatic JNK defi-
ciency was an unexpected finding that may reflect the balance
of positive and negative regulation of PPARg2 expression by
different heterodimeric AP1 transcription factor complexes
(Hasenfuss et al., 2014). Nevertheless, compromised hepatic
AP1 function in LD1,2 mice (Figure S6A) may contribute to
decreased expression of Ncor1 and Nrip1 (Figures S6C and
S6D) and indirectly increase PPARg pathway activity by
reducing corepressor expression.
Hepatic JNK Deficiency Increases Expression of the
PPARa Target Gene Fgf21
Weperformed chromatin immunoprecipitation assays in order to
examine proteins bound to the promoter of the PPARa target
gene Fgf21 (Figure 6A). This analysis demonstrated that JNK
deficiency increased the amount of PPARa bound to the Fgf21
promoter (Figure 6B). We also found that JNK deficiency
reduced the amount of bound NCoR1 (Figure 6C). In contrast,
JNK deficiency did not change the interaction of NRIP1 with
the Fgf21 promoter (Figure 6C). As expected, the reduced inter-
action with NCoR1 was associated with increased histone acet-
ylation on the Fgf21 promoter (Figure 6D). Altogether, these data
indicate that reduced NCoR1 function contributes to increased
PPARa pathway activation caused by JNK deficiency in the liver.
The hepatic PPARa pathway plays a major role in ketogenesis
(Evans et al., 2004; Pyper et al., 2010). The mechanism is medi-
ated, in part, by PPARa-dependent expression of Fgf21
(Badman et al., 2007; Inagaki et al., 2007; Badman et al., 2009;
Potthoff et al., 2009), a gene that is dysregulated by hepatic
JNK deficiency (Figure 3A). Comparison of LWT and LD1,2 mice
demonstrated that JNK deficiency caused increased hepatic
expression of Fgf21 mRNA (Figure 6E), circulating amounts of
FGF21 in the blood (Figure 6F), and ketogenesis (Figure 6G).
Complementation assays demonstrated that restoration of
hepatic NCoR1 expression (Figure 6H) suppressed the effect
of JNK deficiency to cause increased expression of Fgf21
mRNA in the liver (Figure 6I) and the amount of FGF21 circulating
in the blood (Figure 6J). Moreover, shRNA-mediated knockdown
of Ncor1 caused increased hepatic expression of FGF21 (Fig-
ure 5E). Altogether, these data confirm that JNK-regulated
NCoR1 expression contributes to the effects of JNK to inhibit
the PPARa-FGF21 hormone axis.
To test whether increased Fgf21 expression contributes to the
phenotype of LD1,2 mice, we used shRNA to knock down hepatic
Fgf21 expression. Control studies demonstrated that an AAV8-
shFgf21 vector reduced hepatic Fgf21 mRNA expression by
75% ± 7% (mean ± SD; n = 6; p < 0.05). Moreover, the amount
of FGF21 in the blood was reduced in mice treated with the
AAV8-shFgf21 vector in comparison to mice treated with
the control AAV8-shLuc vector (Figure 7A). We found that the
shFgf21 vector prevented the increased ketogenesis (Figure 7B)
and suppressed the improved insulin tolerance (Figure 7C)
caused by hepatic JNK deficiency. These data support the
conclusion that the PPARa-FGF21 hormone axis contributes to
metabolic regulation by hepatic JNK.Cell MeFGF21 Contributes to the Systemic Metabolic Effects of
Hepatic JNK Deficiency
FGF21 regulates adipose tissue metabolism in part by reducing
PPARg inhibitory sumoylation (Dutchak et al., 2012) and
increasing PGC1a expression (Potthoff et al., 2009; Fisher
et al., 2012). Therefore, we examined LWT and LD1,2 mice to
investigate whether hepatic JNK might regulate a FGF21/
PPARg-PGC1a axis in adipose tissue. Analysis of epididymal
adipose tissue sections demonstrated that the HFD-induced
hypertrophy and macrophage infiltration of LWT adipose tissue
were reduced in LD1,2 mice (Figure S7A). Gene expression
analysis demonstrated decreased expression of macrophage
genes, including genes associated with both M1 and M2
polarization, and reduced expression of the adipokine Leptin
(Figure S7B). These observations are consistent with the
decreased obesity of HFD-fed LD1,2 mice in comparison to
HFD-fed LWT mice (Figures 1D, S1A, and S1B). We found that
LD1,2 mice exhibited increased expression of the adipose tissue
PPARg target genes Adiponectin (Holland et al., 2013; Lin
et al., 2013) and Fgf21 (Muise et al., 2008; Wang et al., 2008)
in comparison to LWT mice (Figure S7B). FGF21-stimulated
Pgc1a expression has been implicated in the brown-like adap-
tation of subcutaneous white adipose tissue (Fisher et al.,
2012). Indeed, we found increased expression of brown-like
genes in the inguinal adipose tissue of HFD-fed LD1,2 mice in
comparison to HFD-fed LWT mice (Figure S7C). Altogether,
these data indicate that FGF21 contributes to the systemic
metabolic effects of hepatic JNK deficiency.
DISCUSSION
The liver is a critical organ that orchestrates metabolism within
the body. In the fed state, hepatic lipogenesis is increased, and
the liver can export triglycerides in the form of very-low-density
lipoprotein to peripheral tissues. In contrast, fasting increases
hepatic fatty acid oxidation and the delivery of ketone bodies
to peripheral tissues. The reprogramming of liver function be-
tween these two metabolic states is mediated in part by endo-
crine hormones (insulin, glucagon, FGF15/FGF19, and FGF21)
(Potthoff et al., 2012). The metabolic transition also involves
key signal transduction pathways that are differentially acti-
vated during feeding and starvation. For example, the PPARa
pathway plays an important role during starvation by increasing
fatty acid oxidation and ketogenesis and promoting insulin
sensitivity (Evans et al., 2004; Pyper et al., 2010). In contrast,
the JNK signaling pathway is active in the fed state and is impli-
cated in hepatic steatosis and insulin resistance (Davis, 2000;
Sabio and Davis, 2010). These opposing actions of the PPARa
and JNK signaling pathways contribute to a metabolic switch
that can determine liver function.
This study demonstrates that JNK plays a major role in the
regulation of hepatic metabolism by inhibiting nuclear hormone
receptor pathways, including PPARa, that increase fatty acid
oxidation and ketogenesis. Multiple PPARa target genes likely
contribute to these actions of JNK, but Fgf21 plays a key role
in ketogenesis (Badman et al., 2007, 2009), insulin sensitivity
(Holland et al., 2013; Lin et al., 2013), glycemia (Kharitonenkov
et al., 2005; Xu et al., 2009a, 2009b), and obesity (Kharitonenkov
et al., 2005; Coskun et al., 2008). Indeed, suppression of FGF21tabolism 20, 512–525, September 2, 2014 ª2014 Elsevier Inc. 517
Figure 3. Hepatic JNK Suppresses the PPARa Pathway and Fatty Acid Oxidation
(A) Fgf21 mRNA expression by primary hepatocytes obtained from LWT, LD1, LD2, and LD1,2 mice was measured by quantitative RT-PCR assays (mean ± SEM;
n = 6; **p < 0.01, ***p < 0.001).
(B and C) Heatmap representation of RNA-seq analysis of hepatic genes in overnight fasted HFD-fedmice with the expression profile LD1 < LWT < LD2 < LD1,2. The
genes are displayed with lowest expression (top) to highest expression (bottom) in LD1 liver. Gene Ontology analysis of these genes is presented (C).
(D–F) Seahorse XF24 analysis was performed using primary hepatocytes isolated from LWT and LD1,2 mice. Mitochondrial oxygen consumption rate (OCR) in the
presence of 200mMpalmitate and BSA, 15mMglucose, or 1 mM pyruvate and 10mM lactate (D). Glucose production rate per mg protein in the presence of 1mM
pyruvate and 10mM lactate (E). Lactate production by LWT and LD1,2 hepatocytes (incubated with 15mM glucose) and the effect of treatment of LWT hepatocytes
with 15 mM 2-deoxyglucose (2DG) or 100 nM rotenone (Rot; F). The data presented are the mean ± SEM; n = 10-15; *p < 0.05; **p < 0.01; ***p < 0.001.
(legend continued on next page)
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Figure 4. Hepatic JNK Deficiency Increases
Peroxisome number and Mitochondrial Size
(A and B) LWT and LD1,2 mice were fed HFD
(16 weeks). Sections of the liver were examined by
transmission electron microscopy. Representative
images are presented. Nucleus, N; lipid droplet,
LD. Arrow heads indicate peroxisomes (A) and
mitochondria (B).The scale bar represents 2 mm (A)
and 0.5 mm (B).
(C and D) The number of peroxisomes (C)
and mitochondria (D) per field was measured
(mean ± SEM; n = 30; *p < 0.05).
(E) Relative mitochondrial DNA copy number was
measured (mean ± SEM; n = 3).
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ciency on insulin sensitivity and ketogenesis (Figure 7). There-
fore, the PPARa-FGF21 hormone axis is an important target of
the hepatic JNK signaling pathway that regulates metabolism.
Our analysis establishes that JNK inhibits PPARa target gene
expression in the liver. This effect of JNK is not mediated by
changes in the expression of PPARa (or its partner RXRa) but
is associated with reduced expression of the corepressors
NCoR1 and NRIP1 (Figures 5B and 5C). ChIP assays demon-
strated that JNK deficiency changes the interaction of PPARa
(increased) and NCoR1 (reduced) with a PPRE in the promoter
of the PPARa target gene Fgf21 (Figures 6A–6C). This reduction
in corepressor binding is sufficient to account for PPARa
pathway activation (Perissi et al., 2010; Mottis et al., 2013) and
may be caused by the reduced corepressor expression detected
in mice with hepatic JNK deficiency (Figures 5B and 5C). Indeed,
shRNA studies demonstrated that Ncor1 knockdown was suffi-
cient to cause increased hepatic FGF21 expression (Figure 5E).
Moreover, restoration of Ncor1 expression in the liver prevented
PPARa pathway activation (Figure 5F) and FGF21 expression
(Figures 6I and 6J) and improved glucose tolerance (Figure 5G)
caused by JNK deficiency. These data demonstrate that JNK
promotes repression of PPARa target gene expression by regu-
lating corepressor function.
The presence of AP1 sites in the Ncor1 and Nrip1 promoters
(Figure S6C and S6D) suggests that these genes may be direct
targets of a hepatic JNK signaling pathway that activates AP1
(Figure S6A), but other transcription factors or indirect mecha-
nisms (e.g., miRNA pathways) may also contribute to JNK-regu-(G) Differentially expressed glycolysis, tricarboxylic acid cycle, and electron transport chain genes identified
mice in comparison to HFD-fed LWT are illustrated (padj < 0.05).
(H) LWT and LD1,2 mice were fed a chow diet or a HFD (16 weeks). Sections of the liver were stained with hem
(I–K) Gene expression in the liver of overnight fasted LWT and LD1,2 mice was measured by quantitative RT-P
**p < 0.01).
See also Figures S3 and S4.
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Additional analysis will be required to
define the mechanism of corepressor
regulation by hepatic JNK. Nevertheless,
it is established thatNcor1mRNA expres-
sion is dynamically regulated by exposure
of cells to fatty acids and other stimuli thatcan activate JNK (Yamamoto et al., 2011). Indeed, JNK-stimu-
lated Ncor1 gene expression may contribute to this dynamic
regulation and cause JNK-mediated repression of the PPARa
pathway.
Additional studies will be required to test whether PPARa
pathway repression is mediated exclusively by JNK-regulated
expression of the corepressors NCoR1 and NRIP1. Our analysis
does not exclude the possibility that additional factors may
contribute to corepressor regulation. Examples include roles
for alternative splicing, phosphorylation, nuclear and cyto-
plasmic transport, protein stability (sumoylation), and protein
instability (ubiqutination) (Perissi et al., 2010; Mottis et al.,
2013). The possible regulation of NCoR1 degradation by JNK
is intriguing because studies of AP1 regulation in macrophages
have established that cJun phosphorylation triggers the dissoci-
ation and subsequent degradation of NCoR1 (Ogawa et al.,
2004). Whether this mechanism is relevant to the PPARa
pathway is unclear. Nevertheless, a recent study has highlighted
NCoR1 protein turnover as an important regulatory mechanism
for gene expression related to energy metabolism (Catic et al.,
2013).
The regulation of NCoR1 and NRIP1 expression by JNK sug-
gests that mice with hepatic JNK deficiency may exhibit altered
function of multiple nuclear receptors. For example, hepatic
NCoR1 functions as a potent inhibitor of thyroid hormone
signaling (Feng et al., 2001; Astapova et al., 2008; Fozzatti
et al., 2011), and we found that hepatic JNK deficiency caused
increased thyroid hormone-dependent gene expression (Fig-
ure S5). Similarly, both NCoR1 and NRIP1 inhibit the nuclearby RNA-seq analysis in the liver of HFD-fed LD1,2
atoxylin and eosin. The scale bar represents 25 mm.
CR assays of mRNA (mean ± SEM; n = 8; *p < 0.05;
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Figure 5. Hepatic JNK inhibits PPARa-Dependent Gene Expression
(A) Primary hepatocytes were obtained from LWT and LD1,2 mice and incubated with solvent (DMSO, control), PPARa agonists (50 mM WY14043 or 100 mM
Fenofibrate), or PPARa antagonists (10 mM GW6471 or 20 mM MK886) for 16 hr. PPARa target gene (Acox1, Ehhadh, and Pdk4) expression was examined by
measurement of mRNA by quantitative RT-PCR analysis (mean ± SEM; n = 6; ***p < 0.001).
(B) The expression of Ppara, Rxra, Ncor1, Ncor2, and Nrip1 mRNA by LWT and LD1,2 primary hepatocytes was measured by quantitative RT-PCR analysis
(mean ± SEM; n = 6; ***p < 0.001).
(C) LWT and LD1,2 primary hepatocytes were examined by immunoblot analysis by probing with antibodies to PPARa, NCoR1, NCoR2, NRIP1, JNK, and GAPDH.
(D) Primary wild-type hepatocytes were treated (12 hr) with DMSO (vehicle) or 1mM JNK-in-8 (a small molecule JNK inhibitor) prior to measurement of mRNA
expression by quantitative RT-PCR analysis (mean ± SEM; n = 6; *p < 0.05, **p < 0.01, ***p < 0.001). The effect of treatment (8 hr) of the hepatocytes with DMSO
(NT) or 100 mM Fenofibrate (Fibrate) was examined.
(E) Recombinant AAV8 vectors were employed to express Control shRNA or Ncor1 shRNA in the liver of HFD-fed (4 weeks) LWT and LD1,2 mice. Hepatic mRNA
expression at 10–16 days postinfection was examined by quantitative RT-PCR analysis (mean ± SEM; n = 14–15; *p < 0.05, **p < 0.01).
(legend continued on next page)
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Figure 6. The FGF21 Pathway Is Repressed by JNK
(A–D) Chromatin immunoprecipitation (ChIP) assays were performed with liver isolated from overnight fasted LWT and LD1,2 mice with antibodies to nonimmune
immunoglobulin (control), PPARa, NCoR1, NRIP1, and acetyl-lysine16 histone H4 (H4K16ac). The fold enrichment of a fragment of the Fgf21 promoter with a
PPRE site was measured by quantitative PCR analysis (mean ± SEM; n = 6; p < 0.05).
(E) The hepatic expression of Fgf21 mRNA in overnight fasted mice was examined by quantitative RT-PCR analysis (mean ± SEM; n = 8; ***p < 0.001).
(F) The concentration of FGF21 in the blood of chow-fed and HFD-fed LWT and LD1,2 mice was measured by ELISA. Blood was collected frommice fed ad libitum
or fasted overnight (mean ± SEM; n = 6 *p < 0.05, **p < 0.01).
(G) Ketone body production was measured in overnight fasted LWT and LD1,2 mice challenged (6 hr) without (control) and with octanoate (mean ± SEM; n = 5;
*p < 0.05).
(H–J) NCoR1 or GFP (control) were expressed in the liver of HFD-fed (4 weeks) LWT and LD1,2 mice with recombinant adenovirus vectors (10–16 days). The mice
were fasted overnight and hepatic expression of NCoR1 and GAPDH were examined by immunoblot analysis (H). The amount of Fgf21mRNA was measured by
quantitative RT-PCRanalysis (I) and the concentration of FGF21 in the bloodwasmeasured by ELISA (J). The data presented are themean ±SEM; n = 6; *p < 0.05,
**p < 0.01.
See also Figure S7.
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Signal Transduction by Hepatic JNKhormone receptor liver X receptor (LXR) (Herzog et al., 2007;
Astapova et al., 2008). Therefore, JNK deficiency may also regu-
late LXR, crosstalk with the PPARa pathway (Boergesen et al.,
2012), and contribute to the regulation of hepatic lipid meta-
bolism (Beaven et al., 2013). These considerations indicate
that there is potential for significant complexity in the hepatic
nuclear receptor signaling network that is regulated by JNK.(F and G) NCoR1 or GFP (control) were expressed in the liver of HFD-fed (4 weeks)
hepatic expression of Acox1, Ehhadh, and Pdk4mRNA was measured by quantit
(G). The data presented are the mean ± SEM (n = 6; *p < 0.05, ***p < 0.001).
See also Figures S5 and S6.
Cell MeAdditional studies will be required to determine the roles of these
nuclear receptors (including farnesoid X receptor, glucocorticoid
receptor, hepatocyte nuclear factor 4, LXR, and thyroid hormone
receptor) in the metabolic response to JNK activation. Never-
theless, our analysis establishes that the PPARa-FGF21 hor-
mone axis is an important mediator of metabolic regulation by
hepatic JNK.of LWT and LD1,2 mice with recombinant adenovirus vectors (10–16 days). The
ative RT-PCR analysis (F). The mice were examined by glucose tolerance tests
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Figure 7. FGF21 Mediates Metabolic
Effects of Hepatic JNK Deficiency
(A) AAV8 vectors were employed to express con-
trol shRNA and Fgf21 shRNA in the liver. The mice
were fed HFD (4 weeks). FGF21 in the blood of
mice fed ad libitum or fasted overnight was
measured by ELISA (mean ± SEM; n = 6; *p < 0.05).
(B) Ketogenesis was examined in HFD-fed mice
that were fasted overnight and then challenged
with octanoate (6 hr) by measurement of blood
b-hydroxybutyrate (mean ± SEM; n = 15–30; p <
0.05). The data are normalized to blood
b-hydroxybutyrate in control mice at 0 hr (100%).
(C) Insulin tolerance tests (ITT) were performed on
HFD-fed mice. The time course of blood glucose
clearance and the area under the curve (AUC) are
presented (mean ± SEM; n = 15–30; *p < 0.05,
**p < 0.01).
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The activity of hepatic JNK is regulated by starvation and
feeding. These changes in JNK activity regulate the hepatic
PPARa-FGF21 hormone axis. Studies of mice with hepatic
JNK deficiency demonstrate an exaggerated starvation
response (increased ketogenesis) and a reduced response to
feeding (protection against hyperglycemia and insulin resis-
tance). These responses are mediated, in part, by the hepatic
PPARa-FGF21 hormone axis. Therefore, hepatic JNK plays a
key role in diet-mediated metabolic regulation.
EXPERIMENTAL PROCEDURES
Mice
We have previously described Jnk1LoxP/LoxP mice (Das et al., 2007) and
Jnk2LoxP/LoxP mice (Han et al., 2013). C57BL/6J mice (stock number 000664)
and B6.Cg-Tg(Alb-cre)21Mgn/J mice (stock number 003574) (Postic et al.,
1999)were obtained from theJacksonLaboratory. Themicewerebackcrossed
to the C57BL/6J strain (ten generations) and housed in a facility accredited by
the American Association for Laboratory Animal Care. The mice employed in
this study were LWT (Cre+), LD1 (Cre+ Jnk1LoxP/LoxP), LD2 (Cre+ Jnk2LoxP/LoxP),
and LD1,2 (Cre+ Jnk1LoxP/LoxP Jnk2LoxP/LoxP). All studies were performed with
male mice (8–24 weeks old). Male mice (8 weeks old) were fed a standard con-
trol (chow) diet orHFD (IsoPro3000, Purina, andF3282; Bioserve).Whole-body
fat and lean mass were noninvasively measured with 1H-MRS (Echo Medical
Systems). The animal studies were approved by the Institutional Animal Care
and Use Committee of the University of Massachusetts Medical School.522 Cell Metabolism 20, 512–525, September 2, 2014 ª2014 Elsevier Inc.Viral Transduction Studies
The AAV vector pAAVscCB6siFluc EGFP
that expresses an shRNA that targets luciferase
was modified by exchanging the luciferase
shRNA sequence (BamH1 sites) with a
sequence that encodes an Fgf21 shRNA (50-GA
TCAAAAAAGGGATTCAACACAG GAGAAACTT
CGGTTTCTCCTGTGTTGAATCCC-30). The vec-
tor pAAV-RFP-U6 used to express Ncor1
shRNA (target sequence 50-CGGCATAATCTT
GACAACCTT-30) was obtained from Vector Bio-
labs. Recombinant AAV serotype 8 (AAV8) was
prepared and amplified by the University of Mas-
sachusetts Gene Therapy Vector Core (Mueller
et al., 2012; Ahmed et al., 2013). Male mice
(8 weeks old) were treated by intravenous injection
(tail vein) with 33 1011 genomic copies per mouse
of AAV8-shLuc (control), AAV8-shFgf21, or AAV8-shNcor1 (200 ml final volume). Studies were performed 30–90 days
postinfection.
Complementation studies were performed with Ad-GFP (control) and
Ad-NcoR1 (NM_001252313) adenovirus stocks obtained from Applied Biolog-
ical Materials. Male mice (8 weeks old) were fed HFD (4 weeks) and then
treated by intravenous injection (tail vein; 200 ml final volume) with 8 3 109
genomic copies per mouse of recombinant adenovirus. Studies were per-
formed 10–16 days postinfection.
Blood Analysis
Blood glucose was measured with an Ascensia Breeze 2 glucometer (Bayer).
b-hydroxybutyrate was measured by colorimetric assays (Wako). Insulin and
TSH in plasma were measured by multiplexed ELISA with a Luminex 200
machine (Millipore). T3 and T4 (Calbiotech) and FGF21 (Millipore) in plasma
were measured with ELISA kits. Serum triglyceride was measured with a kit
(Sigma-Aldrich). Lipoprotein analysis was performed by the University of
Cincinnati Mouse Metabolic Phenotyping Center.
Glucose, Insulin, and Pyruvate Tolerance Tests
Glucose and insulin tolerance tests were performed by intraperitoneal injection
ofmicewith glucose (1g/kg), insulin (0.5 U/kg), or pyruvate (1g/kg) according to
methods described previously (Sabio et al., 2008).
Hepatic Lipogenesis
Micewere starved overnight and refed (3 hr). Lipogenesiswas examined in vivo
by injecting mice with 20 mCi/g 3H2O and measurement of radioactivity incor-
poration by scintillation counting with adjustments for 3H2O-specific activity
and tissue mass (Stansbie et al., 1976; Zhang et al., 2006).
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Ketone body formation in vivo was measured with the ketogenic substrate
octanoate (McGarry and Foster, 1971). In brief, mice starved overnight were
subjected to intraperitoneal injection of 10 ml/g of 250 mM sodium octanoate
in sterile water prior to measurement of b-hydroxybutyrate in the blood (Potth-
off et al., 2009).
Hyperinsulinemic-Euglycemic Clamp Studies
The clamp studies were performed by the UMASS Mouse Metabolic Pheno-
typing Center. After an overnight fast, a 2 hr hyperinsulinemic-euglycemic
clamp was conducted in conscious mice with a primed and continuous
infusion of human insulin (150 mU/kg body weight priming followed by
2.5 mU/kg/min; Humulin; Eli Lilly), and 20% glucose was infused at variable
rates to maintain euglycemia (Kim et al., 2004).
Metabolic Cage Analysis
The analysis was performed by the Mouse Metabolic Phenotyping Center at
the University of MassachusettsMedical School. Themice were housed under
controlled temperature and lighting with free access to food and water with
metabolic cages (TSE Systems).
Statistical Analysis
Differences between groups were examined for statistical significance with a
Student’s test and ANOVA with the Fisher’s test.
ACCESSION NUMBERS
Gene expression data were deposited to the NCBI Gene Expression Omnibus
under accession number GSE55190.
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